Immuron Limited

The momentum for this stock is not very good. Immuron Limited is not a good growth stock. Immuron Limited is not very popular among insiders. Immuron Limited is a mediocre stock to choose.

Immuron Ltd. engages in the research and development of oral immunotherapy treatments using dairy-de...

News

Immuron announces new DoD research award for NMRC

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan

Globe Newswire Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16...\n more…

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

Globe Newswire MELBOURNE, Australia, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that...\n more…

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

Globe Newswire MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be...\n more…

BNYMC Group Reduces Stake in Immuron Limited

TipRanks Financial Blog Immuron Limited (AU:IMC) has released an update. The Bank of New York Mellon Corporation (BNYMC) Group has reported a change in their substantial holding in Immuron...\n more…